Abstract
Drugs that target microtubules are a successful class of anti-cancer agents that have been in clinical use for over two decades. Acquired resistance to these drugs, however, remains a serious problem. Microtubule alterations, such as tubulin mutations and altered β- tubulin isotype expression, are prominent factors in development of resistance. Changes in actin and intermediate filament proteins can also mediate sensitivity to microtubule-targeting drugs. This review focuses on the mechanisms by which alterations in cytoskeletal proteins lead to drug resistance. This information will be helpful for improving the targeting of microtubule toxins.
Keywords: Actin, Cytoskeleton, Drug resistance, Intermediate filament, MDR, Microtubule, Microtubule-targeting drugs, C-terminal amino acids, Microfilaments, microtubule-destabilizers
Anti-Cancer Agents in Medicinal Chemistry
Title:Cytoskeletal Alterations that Confer Resistance to Anti-tubulin Chemotherapeutics
Volume: 13 Issue: 1
Author(s): Arun Kanakkanthara, Paul H. Teesdale-Spittle and John H. Miller
Affiliation:
Keywords: Actin, Cytoskeleton, Drug resistance, Intermediate filament, MDR, Microtubule, Microtubule-targeting drugs, C-terminal amino acids, Microfilaments, microtubule-destabilizers
Abstract: Drugs that target microtubules are a successful class of anti-cancer agents that have been in clinical use for over two decades. Acquired resistance to these drugs, however, remains a serious problem. Microtubule alterations, such as tubulin mutations and altered β- tubulin isotype expression, are prominent factors in development of resistance. Changes in actin and intermediate filament proteins can also mediate sensitivity to microtubule-targeting drugs. This review focuses on the mechanisms by which alterations in cytoskeletal proteins lead to drug resistance. This information will be helpful for improving the targeting of microtubule toxins.
Export Options
About this article
Cite this article as:
Kanakkanthara Arun, H. Teesdale-Spittle Paul and H. Miller John, Cytoskeletal Alterations that Confer Resistance to Anti-tubulin Chemotherapeutics, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (1) . https://dx.doi.org/10.2174/1871520611307010147
DOI https://dx.doi.org/10.2174/1871520611307010147 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular-Targeted and Cell-Based Therapies for Sjogren’s Syndrome
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Bladder Cancer Stem Cells: Biological and Therapeutic Perspectives
Current Stem Cell Research & Therapy Pharmacological Modulation of p53 Function in Cancer Therapy
Current Signal Transduction Therapy HER3 and its Ligand, Heregulin, as Targets for Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery The Re-Emergence of Aerosol Gene Delivery: A Viable Approach to Lung Cancer Therapy
Current Cancer Drug Targets Emerging Role of ImmunoPET in Receptor Targeted Cancer Therapy
Current Drug Delivery Role of Genetic and Epigenetic Factors in Oral Squamous Cell Carcinoma - A Structured Review
Recent Patents on Biomarkers Signal Transducer and Activator of Transcription 3 Signaling Pathway: A Potential Target in Sarcoma Treatment
Current Enzyme Inhibition Application and Future Prospect of Extracellular Matrix Targeted Nanomaterials in Tumor Theranostics
Current Drug Targets PET with Non-Standard Nuclides
Current Topics in Medicinal Chemistry A Review of the Current Role of Proton Therapy in Modern Oncology
Current Drug Therapy A Review of the Primer Approximation Multiplex PCR (PAMP) Technique for Detecting Large Scale Cancer Genomic Lesions
Current Bioinformatics Gene Delivery for Cancer Therapy
Current Drug Delivery Oral Precancerous Lesions Show Increased Levels of Glutathione Compared to Cancerous Tissue
Current Nutrition & Food Science Looking out for Cancer Stem Cells’ Properties: The Value-Driving Role of CD44 for Personalized Medicines
Current Cancer Drug Targets MtDNA As a Cancer Marker: A Finally Closed Chapter?
Current Genomics Novel Agents Targeting Bioactive Sphingolipids for the Treatment of Cancer
Current Medicinal Chemistry Anti-Cancer Drug Design Using Natural and Synthetic Pharmacophores
Current Organic Chemistry Epigenetics: Relations to Disease and Laboratory Findings
Current Medicinal Chemistry The Role of Apoptosis in Cancer Development and Treatment: Focusing on the Development and Treatment of Hematologic Malignancies
Current Pharmaceutical Design